Q&A: Gen­mab CEO on ink­ing the first ac­qui­si­tion in the com­pa­ny's 25-year his­to­ry

Gen­mab is an un­usu­al com­pa­ny in phar­ma. In 25 years, it has 44 INDs — 20 of those are still in clin­i­cal de­vel­op­ment — and eight mar­ket­ed med­i­cines. Un­til Wednes­day’s $1.8 bil­lion deal for an­ti­body-drug con­ju­gate mak­er Pro­found­Bio, it had nev­er done a takeover.

But it’s not the drug­mak­er’s first go with AD­Cs. Gen­mab mar­kets Tiv­dak with Pfiz­er, by way of the phar­ma gi­ant’s ac­qui­si­tion of Seagen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER